TG THERAPEUTICS, INC. Increase (Decrease) in Accrued Interest Receivable, Net
TG THERAPEUTICS, INC. (TGTX) reported Increase (Decrease) in Accrued Interest Receivable, Net of $6.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet · last filed 2021-03-01
- TG THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2020-12-31 was $111.00K, a 909.09% increase year-over-year.
- TG THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2020-09-30 was -$64.00K.
- TG THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2020-06-30 was -$1.00K, a 104.17% decline year-over-year.
- TG THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2020-03-31 was -$40.00K.
- TG THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2020 was $6.00K, a 45.45% decline from fiscal 2019.
- TG THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2019 was $11.00K.
- TG THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2018 was -$14.00K, a 156.00% decline from fiscal 2017.
- TG THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2017 was $25.00K.
| Period end | Increase (Decrease) in Accrued Interest Receivable, Net 3 month | Increase (Decrease) in Accrued Interest Receivable, Net 3 month as first filed | Increase (Decrease) in Accrued Interest Receivable, Net 6 month | Increase (Decrease) in Accrued Interest Receivable, Net 6 month as first filed | Increase (Decrease) in Accrued Interest Receivable, Net 9 month | Increase (Decrease) in Accrued Interest Receivable, Net 9 month as first filed | Increase (Decrease) in Accrued Interest Receivable, Net 12 month | Increase (Decrease) in Accrued Interest Receivable, Net 12 month as first filed | Increase (Decrease) in Accrued Interest Receivable, Net 25 month | Increase (Decrease) in Accrued Interest Receivable, Net 28 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $47.00K derived: sum of 2 quarters · filed 2021-03-01 | $46.00K derived: sum of 3 quarters · filed 2021-03-01 | $6.00K 10-K · filed 2021-03-01 | ||||||
| 2020-09-30 | -$64.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$65.00K derived: sum of 2 quarters · filed 2020-11-09 | -$105.00K 10-Q · filed 2020-11-09 | -$94.00K derived: sum of 4 quarters · filed 2021-03-01 | ||||||
| 2020-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$41.00K 10-Q · filed 2020-08-10 | -$30.00K derived: sum of 3 quarters · filed 2021-03-01 | -$40.00K derived: sum of 4 quarters · filed 2021-03-01 | ||||||
| 2020-03-31 | -$40.00K 10-Q · filed 2020-05-11 | -$29.00K derived: sum of 2 quarters · filed 2021-03-01 | -$39.00K derived: sum of 3 quarters · filed 2021-03-01 | -$15.00K derived: sum of 4 quarters · filed 2021-03-01 | ||||||
| 2019-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.00K derived: sum of 2 quarters · filed 2021-03-01 | $25.00K derived: sum of 3 quarters · filed 2021-03-01 | $11.00K 10-K · filed 2021-03-01 | ||||||
| 2019-09-30 | -$10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $14.00K derived: sum of 2 quarters · filed 2020-08-10 | $0.00 10-Q · filed 2019-11-12 | -$42.00K derived: sum of 4 quarters · filed 2021-03-01 | ||||||
| 2019-06-30 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $10.00K 10-Q · filed 2020-08-10 | -$32.00K derived: sum of 3 quarters · filed 2021-03-01 | -$26.00K derived: sum of 4 quarters · filed 2021-03-01 | ||||||
| 2019-03-31 | -$14.00K 10-Q · filed 2020-05-11 | -$56.00K derived: sum of 2 quarters · filed 2021-03-01 | -$50.00K derived: sum of 3 quarters · filed 2021-03-01 | $2.00K derived: sum of 4 quarters · filed 2021-03-01 | ||||||
| 2018-12-31 | -$42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$36.00K derived: sum of 2 quarters · filed 2021-03-01 | $16.00K derived: sum of 3 quarters · filed 2021-03-01 | -$14.00K 10-K · filed 2021-03-01 | ||||||
| 2018-09-30 | $6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $58.00K derived: sum of 2 quarters · filed 2019-11-12 | $28.00K 10-Q · filed 2019-11-12 | -$28.00K 10-Q · filed 2018-11-09 | $137.00K derived: sum of 4 quarters · filed 2020-03-02 | |||||
| 2018-06-30 | $52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $22.00K 10-Q · filed 2019-08-09 | -$22.00K 10-Q · filed 2018-08-09 | $131.00K derived: sum of 3 quarters · filed 2020-03-02 | $88.00K derived: sum of 4 quarters · filed 2020-03-02 | |||||
| 2018-03-31 | -$30.00K 10-Q · filed 2019-05-10 | $79.00K derived: sum of 2 quarters · filed 2020-03-02 | $36.00K derived: sum of 3 quarters · filed 2020-03-02 | $56.00K derived: sum of 4 quarters · filed 2020-03-02 | ||||||
| 2017-12-31 | $109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $66.00K derived: sum of 2 quarters · filed 2020-03-02 | $86.00K derived: sum of 3 quarters · filed 2020-03-02 | $25.00K 10-K · filed 2020-03-02 | $24.62K 10-K · filed 2018-03-15 | |||||
| 2017-09-30 | -$43.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$23.00K derived: sum of 2 quarters · filed 2018-11-09 | -$84.00K 10-Q · filed 2018-11-09 | -$83.85K 10-Q · filed 2017-11-09 | -$108.44K derived: sum of 4 quarters · filed 2019-03-01 | |||||
| 2017-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$41.00K 10-Q · filed 2018-08-09 | -$40.56K 10-Q · filed 2017-08-09 | -$65.44K derived: sum of 3 quarters · filed 2019-03-01 | -$90.75K derived: sum of 4 quarters · filed 2019-03-01 | |||||
| 2017-03-31 | -$61.00K 10-Q · filed 2018-05-10 | -$61.03K 10-Q · filed 2017-05-10 | -$85.44K derived: sum of 2 quarters · filed 2019-03-01 | -$110.75K derived: sum of 3 quarters · filed 2019-03-01 | -$141.09K derived: sum of 4 quarters · filed 2019-03-01 | |||||
| 2016-12-31 | -$24.44K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$49.74K derived: sum of 2 quarters · filed 2019-03-01 | -$80.08K derived: sum of 3 quarters · filed 2019-03-01 | -$102.00K 10-K · filed 2019-03-01 | -$102.17K 10-K · filed 2017-03-16 | |||||
| 2016-09-30 | -$25.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$55.65K derived: sum of 2 quarters · filed 2017-11-09 | -$77.56K 10-Q · filed 2017-11-09 | -$50.07K derived: sum of 4 quarters · filed 2018-03-15 | ||||||
| 2016-06-30 | -$30.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$52.26K 10-Q · filed 2017-08-09 | -$24.76K derived: sum of 3 quarters · filed 2018-03-15 | -$56.55K derived: sum of 4 quarters · filed 2018-03-15 | ||||||
| 2016-03-31 | -$21.91K 10-Q · filed 2017-05-10 | $5.58K derived: sum of 2 quarters · filed 2018-03-15 | -$26.21K derived: sum of 3 quarters · filed 2018-03-15 | $74.40K derived: sum of 4 quarters · filed 2018-03-15 | ||||||
| 2015-12-31 | $27.49K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$4.29K derived: sum of 2 quarters · filed 2018-03-15 | $96.31K derived: sum of 3 quarters · filed 2018-03-15 | $100.50K 10-K · filed 2018-03-15 | ||||||
| 2015-09-30 | -$31.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $68.82K derived: sum of 2 quarters · filed 2016-11-09 | $73.01K 10-Q · filed 2016-11-09 | $104.71K derived: sum of 4 quarters · filed 2017-03-16 | ||||||
| 2015-06-30 | $100.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $104.80K 10-Q · filed 2016-08-09 | $136.49K derived: sum of 3 quarters · filed 2017-03-16 | $115.63K derived: sum of 4 quarters · filed 2017-03-16 | ||||||
| 2015-03-31 | $4.19K 10-Q · filed 2016-05-10 | $35.89K derived: sum of 2 quarters · filed 2017-03-16 | $15.03K derived: sum of 3 quarters · filed 2017-03-16 | $78.59K derived: sum of 4 quarters · filed 2017-03-16 | ||||||
| 2014-12-31 | $31.70K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $10.83K derived: sum of 2 quarters · filed 2017-03-16 | $74.39K derived: sum of 3 quarters · filed 2017-03-16 | $58.35K 10-K · filed 2017-03-16 | ||||||
| 2014-09-30 | -$20.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $42.70K derived: sum of 2 quarters · filed 2015-11-09 | $26.65K 10-Q · filed 2015-11-09 | $53.82K derived: sum of 4 quarters · filed 2016-03-15 | ||||||
| 2014-06-30 | $63.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $47.51K 10-Q · filed 2015-08-10 | $74.68K derived: sum of 3 quarters · filed 2016-03-15 | $74.68K derived: sum of 4 quarters · filed 2016-03-15 | ||||||
| 2014-03-31 | -$16.05K 10-Q · filed 2015-05-11 | $11.12K derived: sum of 2 quarters · filed 2016-03-15 | $11.12K derived: sum of 3 quarters · filed 2016-03-15 | $11.12K derived: sum of 4 quarters · filed 2016-03-15 | $11.12K 10-Q · filed 2014-05-14 | |||||
| 2013-12-31 | $27.17K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $27.17K derived: sum of 2 quarters · filed 2016-03-15 | $27.17K derived: sum of 3 quarters · filed 2016-03-15 | $27.17K 10-K · filed 2016-03-15 | $27.17K 10-K · filed 2014-03-07 | |||||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $0.00 derived: sum of 2 quarters · filed 2014-11-14 | $0.00 10-Q · filed 2014-11-14 | |||||||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-24 | $0.00 10-Q · filed 2014-07-24 | ||||||||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-14 | |||||||||
| 2012-12-31 | $0.00 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |